Abstract
The antibody testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was used to detect the presence of antibodies in a private university setting. This serial cross-sectional study determined the seroprevalence of SARS-CoV-2 antibodies using qualitative and quantitative tests. Between June 2021 to December 2021, samples from 1,318 participants were tested, showing 47.80% of the study population yielding IgG antibodies to SARS-CoV-2 virus. A general increase in seroprevalence was observed from June to December 2021. However, a decreasing trend in IgG reactivity was found in vaccinated individuals over time. IgG antibody formation was observed across all brands of vaccines.
Competing Interest Statement
LBST/JYS/ABCD/ML/AMLA/JW/KA/JPV are funded by special funds from the Offices of the Vice Presidents of the Loyola Schools and Professional Schools of the Ateneo de Manila University. JPV heads one of these offices and played a role in study design, analysis and preparation of the manuscript.
Funding Statement
LBST/JYS/ABCD/ML/AMLA/JW/KA/JPV are funded by special funds from the Offices of the Vice Presidents of the Loyola Schools and Professional Schools of the Ateneo de Manila University. JPV heads one of these offices and played a role in study design, analysis and preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ateneo de Manila University Research Ethics Committee, ASMPH Panel is the ethics review board of the Ateneo School of Medicine and Public Health. It has a Level-2 accreditation by the Philippines Health Research Ethics Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
Data cannot be shared publicly because these are being presented to university officials first. Data are available from the Ethics Committee (contact via researchethics.asmph{at}ateneo.edu) for researchers who meet the criteria for access to confidential data.